IL264167A - Compositions and methods for treating frontotemporal dementia - Google Patents

Compositions and methods for treating frontotemporal dementia

Info

Publication number
IL264167A
IL264167A IL264167A IL26416719A IL264167A IL 264167 A IL264167 A IL 264167A IL 264167 A IL264167 A IL 264167A IL 26416719 A IL26416719 A IL 26416719A IL 264167 A IL264167 A IL 264167A
Authority
IL
Israel
Prior art keywords
compositions
methods
frontotemporal dementia
treating frontotemporal
treating
Prior art date
Application number
IL264167A
Other languages
Hebrew (he)
Original Assignee
Annexon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annexon Inc filed Critical Annexon Inc
Publication of IL264167A publication Critical patent/IL264167A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL264167A 2016-07-19 2019-01-09 Compositions and methods for treating frontotemporal dementia IL264167A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662364013P 2016-07-19 2016-07-19
PCT/US2017/042846 WO2018017711A1 (en) 2016-07-19 2017-07-19 Compositions and methods for treating frontotemporal dementia

Publications (1)

Publication Number Publication Date
IL264167A true IL264167A (en) 2019-02-28

Family

ID=60992917

Family Applications (1)

Application Number Title Priority Date Filing Date
IL264167A IL264167A (en) 2016-07-19 2019-01-09 Compositions and methods for treating frontotemporal dementia

Country Status (6)

Country Link
EP (1) EP3487531A4 (en)
AU (1) AU2017299579A1 (en)
CA (1) CA3030872A1 (en)
IL (1) IL264167A (en)
SG (1) SG11201900123TA (en)
WO (1) WO2018017711A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6462680B2 (en) 2013-07-09 2019-01-30 アネクソン，インコーポレーテッド Anti-complement factor C1q antibody and use thereof
US10723788B2 (en) * 2015-11-24 2020-07-28 Annexon, Inc. Anti-complement factor C1q Fab fragments and uses thereof
CN108159421B (en) * 2018-02-05 2021-05-18 苏州大学 Application of phosphatidylserine blocking agent in preparation of medicine for treating diseases related to platelet quantity reduction
AU2019370485A1 (en) * 2018-11-02 2021-05-13 Annexon, Inc. Compositions and methods for treating brain injury
EP4146276A4 (en) * 2020-05-05 2024-08-14 The J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Gladstone Compositions and methods for treating epilepsy
EP4185612A1 (en) 2020-07-23 2023-05-31 Othair Prothena Limited Anti-abeta antibodies
WO2023287573A2 (en) 2021-07-13 2023-01-19 Mabwell Therapeutics Inc. Anti-c1s antibodies and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007070375A2 (en) * 2005-12-09 2007-06-21 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
US9480658B2 (en) * 2005-12-09 2016-11-01 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
CN104870475B (en) * 2012-10-25 2019-11-08 美国比奥维拉迪维股份有限公司 Anticomplement C1s antibody and its purposes
JP6462680B2 (en) * 2013-07-09 2019-01-30 アネクソン，インコーポレーテッド Anti-complement factor C1q antibody and use thereof
CN107207587B (en) * 2014-11-05 2022-04-19 安尼艾克松股份有限公司 Humanized anti-complement factor C1Q antibodies and uses thereof

Also Published As

Publication number Publication date
WO2018017711A1 (en) 2018-01-25
CA3030872A1 (en) 2018-01-25
EP3487531A4 (en) 2020-03-25
AU2017299579A1 (en) 2019-01-24
EP3487531A1 (en) 2019-05-29
SG11201900123TA (en) 2019-02-27

Similar Documents

Publication Publication Date Title
IL251721A0 (en) Compositions and methods for treating cns disorders
ME03809B (en) Compositions and methods for treating cns disorders
LT3224269T (en) Compositions and methods for treating cns disorders
SI3250210T1 (en) Compositions and methods for treating cns disorders
IL264167A (en) Compositions and methods for treating frontotemporal dementia
HK1258825A1 (en) Methods and compositions for treating hyperhidrosis
EP3209298A4 (en) Compositions and methods for treating insomnia
HK1256298A1 (en) Compositions and methods for treating and preventing neurodegenerative disorders
IL291266A (en) Compositions and methods for treating infections
EP3262065C0 (en) Methods and compositions for treating dystroglycanopathy disorders
EP3445369A4 (en) Compositions and methods for treating dementia
EP3432913A4 (en) Methods and compositions for treating atherosclerosis
IL265255A (en) Compositions for treating dementia
EP3104896A4 (en) Compositions and methods for treating liver injury
EP3265097A4 (en) Compositions and methods for treatment and prevention of pyrexia in horses
SG11201609701UA (en) Pharmaceutical composition for preventing and treating senile dementia and preparation method thereof
EP3416668A4 (en) Methods and compositions for treating melanoma
EP3270919A4 (en) Compositions and methods for treating hepatocellular carcinoma
GB201521083D0 (en) Compositions for treatment and methods thereof